Praveen Tipirneni

Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA.

Sun Microsystems, Inc. provides network computing infrastructure solutions. It offers its solutions under the Java technology platform, Solaris Operating System, MySQL database management system, Sun StorageTek storage solutions, and UltraSPARC processor brands. The company also develops networking computing products and technologies which include servers, storage, open source software, tools, and training. The company provides solutions to the social networking, entertainment, financial services, manufacturing, healthcare, retail, news, energy, and engineering companies. The company was founded in 1982 and is headquartered in Santa Clara, CA.

Fusion MPHC Group, Inc. provides integrated voice and data communication services. It offers broadband Internet access service for small and mid-sized businesses; business phone and Internet services; VPN and security services; email and web hosting services; and enterprise solutions. The firm also provides voice over IP, wireless and voice services on a managed national broadband network, wholesale and carrier services. The company is headquartered in DE.

Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA.

Panacea Acquisition Corp. II operates as a blank check company. It seeks to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 14, 2021 and is headquartered in San Francisco, CA.

Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020.